Search results for: 'Detection of Polluting Carbonaceous Particles biological samples'

Numerous facilities, ranging from research laboratories to hospitals, academic centers and commercial entities, collect human tissues and biomaterials. This study will discuss opportunities, challenges and forecasts for the biobanking automation market globally for the period 2010-2018. Varying requirements of biobanks have urged market participant...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented ...

17 Sep 2018  |  Europe  |  Market Research

Mammography Computer Aided Detection (Mammo CAD) Market in Western Europe, Forecast to 2022

With Low Penetration, Business Models are Capitalizing on Disruptive Innovations

Infographics

×

This insight presents an analysis of the mammography CAD (computer aided detection) market in Western Europe. It provides an in-depth analysis of the current trends, market size, revenue forecast, market penetration and market attractiveness, both in the two dimensional (2D) and three dimensional (3D) CAD markets. X-ray Mammography is the gold sta...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights into recent technological developments for molecular marker detection, drug delivery, cancer immunotherapies and radiopharmaceuticals. The TOE also comprises analysis of innovations across cell and gene therapy, antibody and gene editing platfo...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

08 Jun 2022  |  North America  |  Market Research

Growth Opportunities in Sterile Injectable Outsourcing

Biologics Drive the Future Growth Potential of Sterile Injectable Outsourcing

Infographics

×

Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring of biopharmaceutical products for COVID-19 and next-gen...